Nasdaq
$177.86▲ 0.69%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.03BShares out 56.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 10.8After-hours26.10.09 05:404Ownership#●●●
REPLIGEN CORP
Insider Brian Robb of Repligen Corp reported a change in beneficial ownership of securities on October 6, 2026. This filing serves as a formal disclosure of the insider's equity transaction via Form 4.…more
$177.86+0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Regular26.10.08 00:47SCHEDULE 13G/AOwnership
REPLIGEN CORP
FMR LLC and its affiliates have filed a Schedule 13G/A, reporting their beneficial ownership of Repligen Corp common stock as of September 30, 2026. This filing serves as a joint report for FMR LLC and its associated entities regarding their aggregate holdings.…more
$177.86+0.69%vs prev closeView filingShare - 10.6After-hours26.10.07 05:184Ownership
REPLIGEN CORP
Repligen Corp executive Olivier Loeillot reported changes in beneficial ownership of company securities effective October 5, 2026. This filing serves as a Form 4 statement regarding the insider's holdings.…more
$177.86+0.69%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:30#●●●#●●●
Repligen to Report Third Quarter 2026 Financial Results
Repligen Corporation announced it will report its financial results for the third quarter of 2026 on October 27. The company will host a conference call to discuss its business updates and quarterly performance.…more
$177.86+0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 22:05
●●●●●●●● ●●●●● ●●●●●●
Repligen has officially completed its acquisition of BioLife Solutions, a key developer of cell processing tools for the cell and gene therapy market. This strategic move strengthens Repligen's product portfolio and expands its global footprint in the rapidly growing cell therapy sector.…more
$177.86+0.69%vs prev close - 8.26Pre-market26.08.26 20:30
●●●●●●●● ●●●●● ●●●●●●
Repligen announced its participation in the 21st Annual Wells Fargo Healthcare Conference scheduled for September 9. The event will feature a discussion with company executives, though it remains a standard investor relations activity.…more
$177.86+0.69%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report